Brentuximab vedotin is a potent chemotherapeutic agent that effectively targets B-cell clones responsible for the pathogenesis of MM. In a recent study, findings provides the first evidence of antitumor activity of brentuximab vedotin against refractory MM.
There was no significant difference in the time to progression observed in the brentuximab vedotin (BV) group compared to the placebo group or when brentuximab vedotin was combined with everolimus.
There is a slight but significant familial clustering of SSc. Families with a history of a family member affected with SSc have a greater chance of at least one affected family member. Such observations are important to the medical evaluation and genetic counseling of SSc.
Sclerosis affects all or just part of the body and symptoms can be mild to severe. Examples include arthralgia, dysphagia, skin changes affecting the whole body, or numbness.\n
Current treatments for sclerosis are not effective in many cases, and the current treatment options are limited in scope, while the quality of current information is often limited and poor. Future research is needed to identify and understand the factors underlying the failure of current treatments, as well as to develop better and better treatments for diseases such as sclerosis.
There is a higher rate of sclerosis among men and whites than among Hispanics, non-Hispanic blacks, and Asians, but not among Hispanics or non-Hispanic blacks. The incidence appears to be increasing.
Sclerosis may be caused by genetic and environmental factors. On the cellular level, the changes observed indicate inflammation of the arteries as a cause of the lesions. Finally, the role of viruses is still under investigation.
Sclerotic changes are common in the body and brain for reasons unrelated to dementia. In this situation, it remains important to manage cardiovascular risk factors and reduce alcohol intake.
Sclerosis is the formation of scar tissue and excessive cell proliferation leading to loss of normal lung function. Sclerosis mostly takes place in adults, and can be a cause of breathing problems. Symptoms can include worsening shortness of breath, sweating, and chest pain. To help understand the pathology of sclerotic diseases a detailed history is required with a full physical examination. There are many ways to classify the different types of sclerotic diseases. The cause of sclerotic disease is still unknown. Prostate cancer can develop into a harder form of sclerotic disease called benign prostatic hyperplasia.
Brentuximab vedotin has been shown to significantly reduce the median PFS compared to [brentuximab] vedotin. Brentuximab vedotin had a safety profile similar to [brentuximab] vedotin, and was well tolerated. The new drug is expected to be well-accepted by the medical community, though it will continue to face competition from [brentuximab] vedotin.
Most patients will not develop SSc complications by their late 50s or early 60s, although a large percentage will develop SSc-related complications even if SSc is detected with less than 90-day latency between the time of symptom onset and the time of diagnosis in most cases.
Brentuximab vedotin is currently the only investigational product approved in any country in the United States for any chronic autoimmune disease or cancer treatment in patients who are ineligible for CAR-T cell therapy. The data from the current cohort of 5,000 patients treated in the USA are encouraging, as patients treated on this pathway experience durable, objective responses, with some patients achieving remissions.